By John Russell, Contributing Editor, Bio-IT WorldHow Did We Get Into This Mess? It’s hardly a secret that today’s pharmaceutical and biotech companies are drowning under a deluge of digital images and other types of rich data. From Next-Gen DNA sequencing to high content screening (HCS) to in vivo whole animal imaging, these complex and rapidly evolving technologies are opening important avenues of scientific exploration across drug discovery and development. However, they also present IT organizations with the challenge of managing large, diverse data sets. There are, of course, many types of rich data, and covering the specifics of how best to manage all of them is beyond the scope of a single brief paper.
This paper focuses on digital imaging data, which is perhaps the most varied of all rich data and remains the most widely used in drug discovery and development. Importantly, the issues around managing digital images reflect rich data management challenges generally.
Note: By downloading this whitepaper, you are giving permission to share your contact information with its sponsor.
Five years from now, will sequencing centers have enough capacity to meet global demand?